Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead (NASDAQ:RIGL)
· seekingalpha.com
Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market. Read why RIGL stock is a Buy.
Rigel Pharmaceuticals ( RIGL ) is now a four-drug company, with a clinical catalyst ahead for a potential fifth drug. When I wrote about RIGL in January, I rate...